← Evidence map

ArticleNature biotechnology2026

From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping.

Garth W Strohbehn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 42581119